This trial is testing the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before or has come back.
1 Primary · 8 Secondary · Reporting Duration: Up to 1 year
Experimental Treatment
20 Total Participants · 1 Treatment Group
Primary Treatment: Venetoclax · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: